Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):729–731. doi: 10.1038/bjc.1994.384

A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer.

I S Fentiman 1, A Howell 1, H Hamed 1, S M Lee 1, M Ranson 1, J Wall 1, M A Chaudary 1, C M Ash 1, W M Gregory 1, R A Sellwood 1, et al.
PMCID: PMC2033384  PMID: 7917929

Abstract

A randomised clinical trial has been conducted to compare adjuvant tamoxifen, 20 mg daily, with tamoxifen and prednisolone, 7.5 mg daily, in post-menopausal women with operable breast cancer. There were 254 evaluable patients, of whom 128 were given tamoxifen alone and 126 received tamoxifen and prednisolone. After a median follow-up of 48 months there was no significant difference in relapse-free or overall survival of the two groups. Furthermore, with survival slightly favouring tamoxifen, confidence intervals on the hazard ratio established that a difference in favour of tamoxifen plus prednisolone of even 5% at 5 years was very unlikely (P < 0.02). Thus, despite the relatively small number of patients in this trial, the data clearly establish that prednisolone is not of value as an additional adjuvant agent.

Full text

PDF
729

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DiMartino L., Demontis B., Mitchell I. P., Hayward S. W., Deshpande N. A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. Anticancer Res. 1991 Mar-Apr;11(2):869–872. [PubMed] [Google Scholar]
  2. Fentiman I. S., Saad Z., Caleffi M., Chaudary M. A., Fogelman I. Tamoxifen protects against steroid-induced bone loss. Eur J Cancer. 1992;28(2-3):684–685. doi: 10.1016/s0959-8049(05)80125-x. [DOI] [PubMed] [Google Scholar]
  3. Freedman L. S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982 Apr-Jun;1(2):121–129. doi: 10.1002/sim.4780010204. [DOI] [PubMed] [Google Scholar]
  4. Goldhirsch A., Gelber R. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr. 1986;(1):55–70. [PubMed] [Google Scholar]
  5. Ingle J. N., Mailliard J. A., Schaid D. J., Krook J. E., Gesme D. H., Jr, Windschitl H. E., Pfeifle D. M., Etzell P. S., Gerstner J. G., Long H. J. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer. 1991 Jul 1;68(1):34–39. doi: 10.1002/1097-0142(19910701)68:1<34::aid-cncr2820680107>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  6. Meakin J. W., Allt W. E., Beale F. A., Brown T. C., Bush R. S., Clark R. M., Fitzpatrick P. J., Hawkins N. V., Jenkin R. D., Pringle J. F. Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J. 1979 May 19;120(10):1221–1229. [PMC free article] [PubMed] [Google Scholar]
  7. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rubens R. D., Tinson C. L., Coleman R. E., Knight R. K., Tong D., Winter P. J., North W. R. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer. 1988 Nov;58(5):626–630. doi: 10.1038/bjc.1988.273. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES